Status:

COMPLETED

A Study Evaluating the Use of ResAppDx v2.0 as an Aid to Diagnose Respiratory Disease in Adolescent and Adult Patients in an Emergency Department

Lead Sponsor:

ResApp Health Limited

Conditions:

Asthma Exacerbation

COPD Exacerbation

Eligibility:

All Genders

12+ years

Brief Summary

Aim is to to demonstrate that the ResAppDx v2.0 algorithms provide an accurate diagnosis of respiratory disease in the study's clinical setting compared to a clinical adjudication committee's (CAC) di...

Eligibility Criteria

Inclusion

  • Adolescents and adults aged 12 years and older:
  • Presenting to the study site with current signs or symptoms of rhinorrhea, cough, wheeze, stridor, increased work of breathing, cyanosis, additional auscultatory noises (crepitations), or low oximetry levels.
  • Onset of symptoms must have occurred within 14 days of presenting to the site.

Exclusion

  • 1\. Parent or legal guardian is unwilling or unable to sign the study informed consent form.
  • 2\. Adolescent patient who, in the opinion of the investigator, is able to provide assent based on their age, maturity or psychological state is unwilling or unable to sign the study assent form.
  • 3\. Patient requires mechanical ventilatory support (including invasive, CPAP, or BiPAP) or high flow nasal cannula.
  • 4\. Patient has a history of structural airways abnormalities, tracheobronchomalacia, or vocal cord abnormalities (e.g. laryngomalacia, tracheomalacia, or bronchomalacia).
  • 5\. Patient has any medical contraindication to voluntary cough, including the following (only enroll if coughing spontaneously):
  • a. Severe respiratory distress b. History of pneumothorax c. Eye, chest, or abdominal surgery within 3 months of presenting to the site 6. Hemoptysis within 1 month of presenting to the site. 7. Patient is too medically unstable to participate in study at the discretion of the treating clinician.
  • 8\. Patient has a tracheostomy present and/or has a tracheostomy tube placed. 9. Patient is unable to provide at least 5 coughs (voluntary and/or spontaneous).

Key Trial Info

Start Date :

January 1 2024

Trial Type :

OBSERVATIONAL

Allocation :

ACTUAL

End Date :

February 29 2024

Estimated Enrollment :

171 Patients enrolled

Trial Details

Trial ID

NCT06156462

Start Date

January 1 2024

End Date

February 29 2024

Last Update

March 4 2024

Active Locations (3)

Enter a location and click search to find clinical trials sorted by distance.

Page 1 of 1 (3 locations)

1

Addenbrookes Hospital

London, United Kingdom

2

The Royal London Hospital

London, United Kingdom

3

University College London Hospital

London, United Kingdom